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Abstract
Background
Interleukin (IL)-12 is a pro-inflammatory cytokine that mediates T-helper type 1 responses
and cytotoxic T-cell activation, contributing to its utility as anti-cancer agent. Systemic
administration of IL-12 often results in unacceptable toxicity; therefore, strategies to direct
delivery of IL-12 to tumors are under investigation. The objective of this study was to assist
the preclinical development of NHS-IL12, an immunocytokine consisting of an antibody,
which targets necrotic tumor regions, linked to IL-12. Specifically this study sought to evalu-
ate the safety, serum pharmacokinetics, anti-tumor activity, and immune modulation of
NHS-IL12 in dogs with naturally occurring cancers.
Methodology/Principal Findings
A rapid dose-escalation study of NHS-IL12 administered subcutaneously to dogs with mela-
noma was conducted through the Comparative Oncology Trials Consortium (COTC).
Eleven dogs were enrolled in four dose-escalation cohorts; thereafter, an additional seven
dogs were treated at the defined tolerable dose of 0.8 mg/m2. The expanded cohort at this
fixed dose (ten dogs in total) was accrued for further pharmacokinetics and pharmacody-
namics assessment. NHS-IL12 levels, serum cytokine concentrations, and peripheral blood
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mononuclear cell characterization (post-treatment) and draining lymph node immune profil-
ing, and tumor biopsies (pre- and post-treatment) were collected. Adverse events included
thrombocytopenia, liver enzymopathies, fever, and vasculitis. Correlation between inter-
feron (IFN)-γ induction, adverse events, and NHS-IL12 exposure (maximum concentration
and area under the concentration-time curve) were dose-dependent. Serum IL-10 levels
and intratumoral CD8+ populations increased after treatment. Partial responses, according
to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, were observed in two
dogs treated with NHS-IL12 0.8 mg/m2 and 1.6 mg/m2.
Conclusions/Significance
NHS-IL12 was administered safely to dogs with melanoma and both immunologic and clini-
cal activity was observed. This study successfully defined a narrow therapeutic window for
systemic delivery of NHS-IL12 via the subcutaneous route. Results will inform the design
and implementation of first-in-human clinical trials of NHS-IL12 in cancer patients.
Introduction
The opportunity to treat cancer patients effectively by augmenting or directing anti-tumor
immune responses (i.e. immunotherapy) has increasingly expanded into the clinical arena. The
use of cytokines to stimulate immune responses against cancer has been recognized as an
important component of immunotherapy. Interleukin (IL)-2, tumor necrosis factor (TNF)-α,
interferon (IFN)-α, IL-6, IL-18, and IL-12 are in various stages of development [1–8] Indeed,
the use of IL-2 as a cytokine-based immunotherapy was first used in human patients in 1985,
and was approved in patients with melanoma in 1998 based on durable, but low, complete
response rates (< 10%) [9]. Among potential cytokines, interest in IL-12 is based on its central
role in bridging innate and adaptive immune responses. IL-12 mediates its immune function
by generating T-helper type 1 responses and has shown anti-cancer activity in renal cell carci-
noma, cutaneous T-cell lymphoma, and melanoma [10]. It induces proliferation and activation
of natural killer and T cells to enhance tumor immunity. In addition, IL-12 inhibits tumor
angiogenesis mainly through IFN-γ-dependent production of the chemokine IP-10 [11]. The
clinical development of IL-12 has been hindered by unpredictable and sporadic response rates
and unacceptable toxicity [8,12]. Safety concerns surrounding acute and chronic toxicities, as
well as the reliable prediction of which patients will experience adverse events, remain prob-
lematic for its development [13]. Therefore, strategies to target the delivery of IL-12 to tumors
rather than to normal tissues are needed and are currently being investigated.
NHS-IL12 is a fusion protein comprising two IL-12 heterodimers combined to the H-chain
of an NHS76 monoclonal antibody. NHS76 binds to DNA/histone complexes, thereby target-
ing IL-12 to regions of tumor necrosis where DNA is exposed. Because necrosis is a universal
feature of solid malignancies during tumor growth, NHS76 targeting is thought to have broad
applicability across multiple indications. Murine in-vivo models have shown NHS-IL12 to be
safe and efficacious with a subcutaneous route of administration showing the best results. This
route of administration achieves a slow, sustained release into the bloodstream with enhanced
lymphatic absorption to potentiate immune responses in loco-regional lymph nodes prior to
systemic distribution. However, a greater understanding of the optimal dose, schedule,
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pharmacokinetics, and immunological changes linked to drug exposure are needed to translate
NHS-IL12 into human clinical trials.
Comparative oncology provides an opportunity for translational studies of new cancer ther-
apeutics using pet dogs that have developed cancer naturally [14,15]. Studies in tumor-bearing
dogs can answer questions about a drug’s pharmacokinetics, mechanism of action, pharmaco-
dynamic modulation, and can define more specifically same species dose-toxicity and dose-
response relationships in ways that are difficult to assess in mouse models and human trials
[16]. Comparative oncology studies of immunotherapeutics are particularly informative due to
the presence of a syngeneic host-tumor relationship and a competent immune system. Other
advantages of the dog model are opportunities to serially biopsy naturally-occurring malignant
lesions during a course of therapy, and assess constitutional signs of fatigue or lethargy, which
can be difficult and/or impossible in rodent studies. Tumor vaccines, liposome cytokine deliv-
ery, immunomodulators, and other immunotherapeutics have been evaluated successfully in
dogs with cancer [17–20].
With these comparative- and translational-drug development questions in mind, a clinical
trial to evaluate NHS-IL12 administered subcutaneously was conducted with the aim of defin-
ing its tolerability and immunologic activity in a spontaneous cancer model. The study design
included a fixed-schedule, dose-escalation phase followed by an expanded cohort in dogs with
malignant melanoma. Pharmacokinetic analysis and pharmacodynamic endpoints, including
serum IFN-γ cytokine concentrations and evaluation of changes in both systemic and tumor-
associated immune-cell subsets following NHS-IL12 exposure, were assessed. Serum IL-10
concentrations and intratumoral CD8+ populations increased after NHS-IL12 treatment and
were measurable biomarkers of exposure. Results from this and other comparative studies will
inform the design and implementation of first-in-human clinical trials by defining starting
doses of NHS-IL12 and biomarkers for its exposure.
Results
Study design and patient characteristics
A fixed schedule, dose-escalation (28-day cycle) study design was used to assess the tolerability
of NHS-IL12 administered subcutaneously in dogs with melanoma. This was followed by a
fixed-dose, expanded cohort to refine the exposure-biological response relationships in the
same population. Dose-escalation cohorts initially consisted of one dog per cohort. A rapid
escalation was planned through five dose cohorts (NHS-IL12, 0.4, 0.8, 1.2, 2.4, 3.6 mg/m2 sub-
cutaneously) based on adverse events using modified Veterinary Cooperative Oncology Group
Common Terminology Criteria for Adverse Events (modified VCOG-CTCAE) [21]. Cohorts
were expanded to include three dogs if a grade 2 adverse event was observed or six dogs if
dose-limiting toxicity (DLT; defined in Methods) was observed. A total of 11 dogs were
enrolled in the dose-escalation phase: 0.4 mg/m² (n = 1), 0.8 mg/m² (n = 3), 1.6 mg/m² (n = 4),
2.4 mg/m² (n = 3). An additional seven dogs were enrolled in the fixed-dose (NHS-IL12, 0.8
mg/m² subcutaneously) expanded cohort. NHS-IL12 treatment was administered on day 1 and
serial serum pharmacokinetics and pharmacodynamics (IFN-γ, cytokine profiling, peripheral
blood mononuclear cell [PBMC] immune cell characterization) collections were obtained over
the first 48 hours, and then repeated as indicated in Tables 1 and 2. Tumor biopsies for evalua-
tion of immune cell infiltrates were collected pre- and post-treatment (days 8 and 29, and
monthly thereafter). Response was assessed on day 29 using Response Evaluation Criteria in
Solid Tumors (RECIST) criteria [22,23]. Immunogenicity (anti-NHS-IL12 antibodies) was
measured in all dogs. Dogs had naïve or recurrent malignant melanoma (although one dog was
later reclassified as having an anaplastic sarcoma) and were required to have tumors located
NHS-IL12 in Dogs with Malignant Melanoma
PLOSONE | DOI:10.1371/journal.pone.0129954 June 19, 2015 3 / 20
peripherally to allow access for biopsy. Sex (six castrated males, one intact male, 11 spayed
females), body surface area (range 0.34–1.30 m2), and breed (six mixed breed and 12 purebred)
were recorded for all dogs in the study. Metastatic disease was evident at enrollment in 11/18
treated dogs.
Subcutaneous delivery of NHS-IL12 0.8 mg/m2 was well tolerated in
dogs with melanoma
In total, 18 dogs were enrolled in the study, with 13 completing the planned 28-day study
period. Tolerability was evaluated in all dogs. Adverse events were defined by modified
VCOG-CTCAE criteria and reported uniformly across the multicenter Comparative Oncology
Trials Consortium (COTC) [21]. DLTs were defined as Grade3 events attributed to drug
therapy, excluding transient or non-clinical neutropenia, thrombocytopenia, or hepatic enzy-
mopathy, which were expected events. Adverse events reported that were acute and expected
(fever, hepatic enzymopathy, thrombocytopenia, hypotension, vascular leakage syndrome)
mirrored those of human patients and normal dogs receiving systemic IL-12 treatment.
NHS-IL12 at a dose of 0.8 mg/m² was defined as tolerable in tumor-bearing dogs and was
selected for subsequent evaluation in a fixed-dose expanded cohort. No drug-related serious
adverse events were reported in dogs treated at this dose (n = 10). Dogs that received
NHS-IL12 at doses of 1.6 mg/m² and 2.4 mg/m² experienced Grade 4 or 5 adverse events
(n = 4), thus making these doses unacceptable. Events included thrombocytopenia, fever,
anorexia, pleural effusion, and severe anemia. Suspected drug-related serious adverse events
included systemic vasculitis and/or severe inflammatory response syndrome (SIRS). These
Table 1. Study schedule for dose escalation and cohort expansion of NHS-IL12 administered subcutaneously.
Action Pre-
Tx
Day
1
Day
2
Day
3
Day
8
Day
15
Day
22
Day
29
q. Day
8
q. 28
days
Patient eligibility X
Tumor measurements X X X X X X X
Tumor biopsy X X X X
Draining lymph node fine-needle aspirates X X X X
Serum (IFN-γ, cytokines, drug levels,
immunogenicity)
X X X X X X X X
PBMC immune cell characterization X X X X X X
CBC/chemistry and coagulation profiles/UA X X X X X X
Abdominal ultrasound/thoracic radiographs X X X
NHS-IL12 subcutaneous X X X
Weight measurement X X X X X X X X
Fever monitoring X X X X
Digital photo X X X X X
CBC: complete blood count; IFN, interferon; PBMC, peripheral blood mononuclear cell; Tx: treatment; UA: urinalysis.
doi:10.1371/journal.pone.0129954.t001
Table 2. Serial serum pharmacokinetics and IFN-γ/cytokine panel collections.
Time 0 1 hr 2 hr 4 hr 8 hr 24 hr 32 hr 48 hr Day 8
Serum collection X X X X X X X X X
IFN: interferon.
doi:10.1371/journal.pone.0129954.t002
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results suggest that there is a narrow therapeutic window for NHS-IL12 and additional studies
are needed to refine this window further. Non-drug-related serious events were attributed to
tumor progression and included seizure activity (2.4mg/m2) and, anorexia (0.8mg/m2) (n = 2).
Subcutaneous administration of NHS-IL12 resulted in measurable
serum drug levels
Serum samples, collected to assess systemic exposures of NHS-IL12 after subcutaneous admin-
istration, were available from 15 dogs and NHS-IL12 levels were measurable in all but two
(patients 0201 and 0901; Table 3). Maximum serum concentrations (Cmax) of NHS-IL12 were
dose-dependent, although exposure (area under the concentration-time curve [AUC]) was var-
iable across dosing cohorts (Fig 1). Clearance was prolonged in five dogs with NHS-IL12
detectable for up to 15 days following treatment.
Serum cytokine measurements revealed increased systemic IL-10
levels following treatment with NHS-IL12
Canine serum cytokine panels (IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, IL-15, IL-18, Granulocyte-
macrophage colony-stimulating factor [GM-CSF], IP-10, keratinocyte-derived cytokine [KC],
monocyte chemoattractant protein-1 [MCP-1], TNF-α) were measured before treatment,
serially for 48 hours after NHS-IL12 administration, and thereafter as indicated in Table 1. Of
these analytes, serum IL-10 levels increased after treatment most consistently (in 17/18 dogs);
this increase could be detected as early as four hours after treatment and was statistically signif-
icant at both 48 hours and remained so at 192 hours (Fig 2). There was no difference in the lev-
els of serum IL-10 at 48 hours between the three treatment groups with more than one dog.
The initial elevation in IL-10 did not correlate with clinical response or with the development
of toxicity. There were no other consistent cytokine or chemokine (KC, IL-8, and MCP-1)
changes after one cycle of treatment, although IL-8 and MCP-1 were measurable in all dogs.
Dramatic increases in cytokines and chemokines (GM-CSF, IL-2, IL-7, IL-15, IL-18, MCP-1)
Table 3. Pharmacokinetics of NHS-IL12 in tumor-bearing dogs after subcutaneous administration.
Animal Dose (mg/m2) Dose (ug/kg) Vz (mg/kg) CI (ml/h/kg) AUC (h*ng/ml) Cmax(n/gml) T1/2(h) MRT(h)
0302 0.4 20.4 1,820 40.0 497 6.97 31.6 39.0
0103 0.8 40.8 1,930 29.9 342 8.02 44.9 37.4
1004 0.8 40.8 493 7.86 4,970 91.9 43.5 41.1
0201 0.8 40.8 ND ND ND ND ND ND
0202 0.8 40.8 1,080 31.3 1,290 35.2 23.9 25.6
0203 0.8 40.8 4,840 27.2 1,280 20 123 99.4
0901 0.8 40.8 ND ND ND ND ND ND
0902 0.8 40.8 8,130 59.1 648 3.87 95.4 116
0305 1.6 81.6 6,440 27.3 2,920 36.0 164 111
0501 1.6 81.6 18,900 248 305 7.96 52.6 34.4
0502 1.6 81.6 442 21.9 3,290 152 14.0 15.5
0303 1.6 81.6 1,560 27.6 2,800 33.8 39.1 44.3
0304 2.4 122 1,290 9.01 3,420 85.2 99.2 25.5
1902 2.4 122 655 14.9 5,020 129 30.4 23.7
1903 2.4 122 NA NA 1,620 50.3 NA 29.4
AUC: area under the time-concentration curve; Cl: clearance; Cmax: maximum concentration; MRT: mean residence time; NA: not available, calculation
not possible due to a small number of data points; ND, not detectable; T1/2: half-life.
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were seen in one dog (patient 0201) after repeated administrations of NHS-IL12. This dog
experienced a strong partial response (PR) through nine cycles of treatment.
Serum IFN-γ induction reflected toxicities at higher NHS-IL12 doses
Induction of IFN-γ was detectable in dogs that received NHS-IL12 at a dose of 1.6 mg/m2 or
higher (Fig 3). Elevated serum IFN-γ (> 100 pg/ml) was seen in all dogs experiencing adverse
events. However the highest IFN-γ induction was not seen with the most severe (i.e. Grade 4 or
5) events. IFN-γ levels spiked sharply at 24 hours post-administration of NHS-IL12 and
returned to undetectable levels by 48 hours. 3/4 dogs treated at 1.6mg/m2 did not have evalu-
able serum samples.
Fig 1. Subcutaneous administration of NHS-IL12 resulted in measurable serum drug levels. Serum samples were collected from dogs to define
systemic exposures of NHS-IL12 after subcutaneous administration. NHS-IL12 levels were measured pre-treatment and at 1, 2, 4, 8, 24, 36, and 48 hours
following administration (8-point collection) and on days 8, 15, and 29. NHS-IL12 Cmax was dose-dependent: 0.4 mg/m
2 and 0.8 mg/m2 (A) and 1.6 mg/m2
and 2.4 mg/m2 (B). Clearance was prolonged in some dogs as NHS-IL12 was still measurable in five animals 14 days following treatment.
doi:10.1371/journal.pone.0129954.g001
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Intratumoral CD8+ T cell infiltration increased following NHS-IL12
treatment
Tumor histopathology was graded for necrosis, inflammation, and infiltration of T, B, and den-
dritic cells (CD3-CD4+ and CD8+, CD79a, CD18) pre-treatment and on days 8 and 29 post-
treatment. In the dose-escalation phase, intratumoral CD8+ T-cell populations increased after
Fig 2. Serum IL-10 levels increased following treatment with NHS-IL12. Each line represents a different
dog, with individual colors representing different treatment groups. Serum IL-10 levels at 48 and 192 hours
were significantly different from time points 0–8 hours (Kruskal-Wallis test followed by Dunn’s multiple
comparison test) when data from all dogs was pooled. There was no difference in IL-10 levels at 48 hours
between any of the treatment groups (Kruskal-Wallis test, p = .06, the 0.4 mg/m2 group was not included
because it was a single dog).
doi:10.1371/journal.pone.0129954.g002
Fig 3. Serum IFN-γ induction was associated with NHS-IL12 dose and the observation of adverse events. IFN-γ levels were measured using ELISA
techniques. Induction of IFN-γ was detectable in dogs treated with NHS-IL12 at a dose of 1.6 mg/m2 or higher. IFN-γ levels spiked sharply at 24 hours post-
treatment and returned to undetectable levels by 48 hours. Elevated serum IFN-γ (> 100 pg/ml) was associated with increased risk for toxicity. However the
highest level of IFN-γ induction was not directly linked to the most severe (Grade 4 or 5) adverse events.
doi:10.1371/journal.pone.0129954.g003
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PLOSONE | DOI:10.1371/journal.pone.0129954 June 19, 2015 7 / 20
NHS-IL12 treatment in 5/7 evaluable dogs. Dogs were deemed evaluable if they had at least
two viable tumor biopsies pre- and post-treatment available for immunohistochemical analy-
ses. All dogs with measurable increases in CD8+ T cells post-treatment received NHS-IL12 at a
dose of 0.8 mg/m2 or higher.
Draining lymph node and PBMC flow cytometry analyses did not reveal
distinct trends in immune cell profiling after NHS-IL12 therapy
Relative and absolute numbers of T- and B-cell populations were assessed in blood samples
obtained on days 1, 2, 3, and 8 post-treatment. Subsets analyzed included CD4+, CD8+, and
CD4+Foxp3+ T cells (regulatory T cells [Tregs]) and B cells (CD21+MHCII+). There was a
downward trend in CD4+ T cells at day 8 post-treatment (Fig 4). The same T- and B-cell sub-
sets (obtained by fine needle aspiration) were analyzed in peripheral tumor draining lymph
nodes when readily identifiable on days 1, 8, and 29. Additionally, relative numbers of dendritic
cells (CD11c+) and activated dendritic cells (CD11c+MHCII+) were also measured. No signifi-
cant differences were observed in immune-cell subsets across the time points evaluated (Fig 5).
Immune responses against NHS-IL12
Production of antibodies to human IL12 was expected in this study as a result of the adminis-
tration of humanized antibody to dogs. Antibody titers were measured in two dogs on study
day 8 and in 12 dogs on study days 15 and 29. As expected, day 8 samples were negative, but 8/
12 collected on day 15 or 29 were found to be positive. Host antibody responses were directed
mainly against the human IgG part of the molecule, but 5/14 dogs tested also developed anti-
bodies against a huIL12 portion. In 3/14 dogs (patients 0202, 0203, and 0305) negative titers
were found for NHS-IL12, human IgG, and both huIL-12 subunits (p40 and p70) four weeks
after administration of NHS-IL12. Antibody development did not appear related to the dose of
NHS-IL12 administered.
Clinical activity of systemic NHS-IL12 in dogs with melanoma
Tumor target lesions were identified at enrollment and measurements recorded weekly.
RECIST criteria were used to evaluate response after one cycle of therapy (28 days) in those
dogs achieving an objective response (complete response [CR] or PR) eligible for continued
treatment. Overall, 2/7 dogs in the dose escalation that completed one cycle of therapy achieved
a PR (NHS-IL12, 0.8 mg/m² [patient 0201] and 1.6 mg/m² [patient 0305]), whereas two dogs
had progressive disease (PD) and 3 had stable disease (SD). In addition, patient 0201 (Fig 6)
had a prolonged response to treatment and received NHS-IL12 treatment for over 9 months
before progression was eventually noted. Four dogs were euthanized prior to day 28, one due
to PD and three as a result of drug-related toxicities. In the expanded cohort, seven additional
dogs were treated at 0.8 mg/m²; after one cycle of therapy, five had PD and two had SD. Clini-
cal activity recorded at tolerable doses of NHS-IL12 supports its evaluation in further studies.
Discussion
The clinical utility of cytokines has been hindered by a poor safety profile and incorrectly
designed dosing regimens; immunocytokines, such as NHS-IL12, have the potential to over-
come these liabilities. The goal of this study was to generate comprehensive data on the tolera-
bility and immunological activity of systemic NHS-IL12 in tumor-bearing dogs. Results show
that NHS-IL12 can be safely administered systemically to dogs up to a dose of 0.8 mg/m² and
both immunological and clinical activity was observed. Adverse events were correlated with
NHS-IL12 in Dogs with Malignant Melanoma
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IFN-γ induction and dose of NHS-IL12. Increases in serum IL-10 levels, and tumor-infiltrating
CD8+ T cells, and decreases in PBMC CD4+ populations after NHS-IL12 treatment were linked
to exposure and may be evaluable as biomarkers in the future.
A strong genetic similarity exists between canine and human IL-12, with 84% homology for
the ligand and 68% for the receptor (www.ensembl.org). NHS-huIL12 was used for this study
Fig 4. No significant changes in circulating T- or B-cell populations were seen after treatment with NHS-IL12.Relative numbers of T- and B-cell
populations were quantified in PBMCs by flow cytometric analysis on days 1, 2, 3, and 8 after treatment with NHS-IL12. Immune cell determination was
based on labeling: B cells, CD21+MHCII+ (A),T cells, CD4+ (B) or CD8+ (C); regulatory T cells, CD4+Foxp3+ (D);. CD4+ T cells trended downward at day 8
compared to their baseline measurements (B). Other differences were not evident over the time points evaluated.
doi:10.1371/journal.pone.0129954.g004
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since in-vitro work proved the NHS-huIL12 molecule is active in stimulating IFN-γ production
from canine PBMCs (data not shown). Human IL-12 binds to the canine IL-12 receptor and
invokes an IL-12 mediated response (data not shown). Additionally, earlier studies of nebulized
IL-2 liposomes demonstrated regression of pulmonary metastases and increased bronchial
Fig 5. Tumor draining lymph node T-cell, B-cell or dendritic-cell populations did not change significantly after treatment with NHS-IL12. T-cell, B-
cell, and dendritic cell populations were quantified in regional lymph node aspirates by flow cytometric analysis on days 1, 8, and 29 after treatment with
NHS-IL12. Immune cell determination was based on labeling: B cells, CD21+MHCII+ (A); T cells, CD4+ (B) or CD8+ (C); regulatory T cells, CD4+Foxp3+ (D);
activated dendritic cells, CD11c+MHCII+ (E); and dendritic cells, CD11c+ (F); No significant differences in subsets were observed for the time points
evaluated.
doi:10.1371/journal.pone.0129954.g005
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lymphocyte and lytic effector cell activity in dogs with cancer [24]. These genetic, functional,
and clinical data supported the use of comparative models to evaluate such cytokine-based
therapies.
Results of this study suggest that there is a narrow therapeutic window for NHS-IL12
administration in clinical cancer patients. Doses of 0.8 mg/m2 were well tolerated, while dose
of 1.6 mg/m² and 2.4 mg/m² resulted in Grade 4 or 5 adverse events. Fever, anemia, thrombo-
cytopenia, lethargy and poor appetite were the most consistent Grade 4 or 5 events, with clini-
cal evidence of cytokine-induced acute vasculitis and subsequent peripheral edema with
pleural effusion. Peritoneal hemorrhage, likely secondary to severe thrombocytopenia and clin-
ical evidence of disseminated coagulopathy, was also noted in one patient receiving 2.4 mg/m2.
Fig 6. Clinical activity of NHS-IL12 evident in dogs with malignant melanoma. Patient 0201 had a large malignant melanoma of the right maxilla and
buccal surface. Prior to treatment on day 1, the tumor measured 4.4 cm in longest diameter (A). The dog received 0.8 mg/m2 (1.04 mg) of NHS-IL12
administered subcutaneously. On day 29 RECIST response was assessed and a PR was noted. The tumor measured 2.4 cm, representing a 45% decrease
(B). The dog continued monthly dosing of NHS-IL12 and had no evidence of disease after three cycles of therapy (C). On day 85, despite complete
regression of the lesion, a formal CR could not be assigned to the observed clinical activity in this dog since canine malignant melanoma invades the
underlying bone and a CT scan of the oral cavity was not performed at baseline. No gross disease was noted through nine cycles of therapy. PD eventually
recurred in the neighboring nasal cavity.
doi:10.1371/journal.pone.0129954.g006
NHS-IL12 in Dogs with Malignant Melanoma
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Elevated serum IFN-γ levels (> 100 pg/ml) in dogs treated with 1.6 mg/m2 or higher were
associated with toxicities. However, maximal IFN-γ induction was not directly linked to study
deaths. Drug-related, high-grade, and life-threatening adverse events resulted from systemic
vasculitis and/or SIRS, which are events commonly associated with systemic cytokine therapy.
Additional escalation to cohorts of 1.0 mg/m2 or 1.2 mg/m2 may have helped to further refine
tolerable doses of NHS-IL12 in tumor-bearing dogs and to best guide dose selection for first-
in-human trials. Mining prospective evidence to identify patients who will experience severe
adverse events should be the focus of continued efforts.
Consistent biomarkers of NHS-IL12 exposure were identified. In all but one dogs, a persis-
tent elevation in serum IL-10 was detected after treatment. IFN-γ peaked consistently at 24
hours post-treatment and IL-10 was induced at 48 hours post-treatment. IL-10 levels remained
elevated until or beyond 196 hours, which was the last time point analyzed. This is in keeping
with previous preclinical and clinical reports that have described a persistent upregulation of
IL-10 following treatment with IL-12; the induction of IL-10 has been implicated as a mecha-
nism of IL-12 desensitization and attenuation of clinical activity[25,26]. Contribution of the
immunoregulatory enzyme, indoleamine 2,3-dioxygenase (IDO) via tryptophan depletion or
induction of immunomodulating tryptophan metabolites, should also be considered as a
source of immunologic tolerance [27]. Clinical dosing intervals that allow IL-10 levels to return
to baseline may optimize the clinical activity of NHS-IL12. Immunohistochemical analysis of
tumor biopsies revealed an overall trend towards increased CD8+ T-cell infiltration following
treatment with NHS-IL12, possibly the result of IL-12-induced T-cell proliferation [28,29].
Stimulation of anti-tumor immune responses mediated by CD8+ T cells may be a key mecha-
nism of action through which NHS-IL12 could slow tumor growth.
NHS-IL12 can bind areas of tumor necrosis and thus the extent of necrosis within tumor,
along with overall tumor volume, may potentially influence the PK profile of NHS-Il-12.
Tumor biospies from dogs in the current study were collected most frequently using a Tru-Cut
technique and thus, the physical size of the biopsies was likely not representative of the global
extent of necrosis within tumors. A non-invasive imaging method that can provide a compre-
hensive quantitative assessment of both tumor volume and cell viability within solid tumors,
such as 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
(18FDG-PET/CT), could be considered for future studies with these correlations in mind.
Although the overall objective response rate was low in this exploratory study, there were
promising signs of therapeutic activity. In one dog (patient 0201) a 4.4 cm tumor was observed
to completely regress. This response was characterized as a PR rather than a CR because com-
puted tomography (CT) imaging to define maxillary bone involvement was not performed
prior to treatment. Nine cycles of NHS-IL12 were given but this dog eventually succumbed to
progressive disease in the sinus cavity 11 months after treatment initiation. Interestingly,
serum NHS-IL12 levels were not detected at any pharmacokinetics time point, but measurable
anti-drug antibodies indicated that exposure had occurred. Retreatment resulted in dramatic
increases in cytokine and chemokine levels (GM-CSF, IL-2, IL-7, IL-15, IL-18, MCP-1). All but
IL-18 are T-cell growth factors, but neither IL-7 nor IL-15 are produced by T cells. It is possible
that IL-12 treatment induced expression of these cytokines by antigen-presenting cells and
stroma. Predicting response in this patient was not possible, therefore methods to enhance
NHS-IL12 directed targeting and to improve its reliability should be explored in future studies.
This study described the acute and long-term safety of NHS-IL12 administered subcutane-
ously and established a model for future evaluation of targeted immunocytokines. Immu-
notherapy’s best potential to improve outcome is challenged by Phase III standard of care
requirements and protracted response monitoring needed to measure its effect. Comparative
oncology studies can be conducted upfront in macroscopic and minimal residual disease
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settings and may better identify the therapeutic utility of these approaches. Furthermore, com-
parative efforts may improve the reliability of activity and safety biomarkers for human
patients. Results from this study have been used together with other preclinical data to inform
the design of a Phase I clinical trial of NHS-IL12 in human cancer patients (NCT01417546).
Methods
Comparative Oncology Trials Consortium
The goals and infrastructure of the COTC have been described previously [30–32]. All COTC
trial data are reported electronically and reviewed contemporaneously through the Cancer
Central Clinical Database (C3D) modified for use in canine clinical trials. Trials are centrally
managed and directed through the NCI-Comparative Oncology Program (COP).
Trial eligibility and enrollment
Client-owned pet dogs with histologically confirmed melanoma, favorable performance status
(modified Eastern Cooperative Oncology Group [ECOG] Performance Status grade 0 or 1),
and informed owner consent were eligible for enrollment. Eligibility criteria required a newly
diagnosed or recurrent melanoma, where the measureable tumor was amenable to serial biopsy
and> 3 cm but< 8 cm in the longest diameter. Physical examination and laboratory assess-
ments, including complete blood count (CBC), serum biochemical profile, and urinalysis
(UA), were performed to evaluate eligibility prior to enrollment. Exclusion criteria removed
dogs weighing less than 10 kg, those with significant co-morbidities (such as renal, liver, and
heart failure or coagulopathy), history of immune-mediated disease, or concurrent chemother-
apy, radiation therapy, or biological therapy. Tumor staging included thoracic radiographs
performed prior to study initiation. All dogs were evaluated uniformly and treated within a
defined clinical protocol with Institutional Animal Care and Use Committee (IACUC)
approval at each COTC enrollment site (University of California-Davis, Colorado State Uni-
versity, University of Tennessee, University of Missouri, Texas A&MUniversity, University of
Wisconsin-Madison, and Tufts University). The NCI-COP reviewed the eligibility screening
and approved trial entry of each dog.
Treatment, monitoring and safety assessments
Dogs underwent a complete physical examination, laboratory assessments (CBC, serum bio-
chemical profile, coagulation panel, UA, whole blood, PBMCs, and serum collections), and
pre-treatment biopsies at enrollment. Vital signs (core temperature, pulse, respiratory rate)
were recorded at baseline. Dogs received NHS-IL12 subcutaneously on day 1 according to their
dosing cohort. Dogs remained hospitalized for serial pharmacokinetic analysis, serum IFN-γ/
cytokine and PBMC collections, and temperature measurements over the first 48 hours. Dogs
were discharged into the care of their owners after the 48-hour blood draw. Owners were
required to monitor their dog’s temperature once daily for 5 days after NHS-IL12 administra-
tion. Additionally, owners completed an Owner Assessment Form at baseline (day 0), then
weekly, to record impressions of their dog’s clinical status throughout the study period.
A primary study objective was to define acute and chronic toxicities associated with the sub-
cutaneous administration of NHS-IL12. Expected adverse events were outlined in the study
protocol. Repeat laboratory assessments (CBC, biochemical profile, coagulation panel, and
UA) were performed on days 8, 15, and 29 to define safety. All bloodwork was performed uni-
formly at a laboratory adhering to GLP (Antech Diagnostic Laboratories, Irvine, California).
VCOG-CTCAE v. 1.0 were used to define DLTs [21]. DLTs were defined as any grade 3 or 4
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hematologic or non-hematologic toxicities. Transient (< 24 hours) grade 3 or 4 neutropenia,
thrombocytopenia, or fever associated with grade 2 or less lethargy/fatigue, or transient grade 3
increases in hepatic enzymes (alanine aminotransaminase, aspartate aminotransaminase up
to> 10x upper limit of normal [ULN] and/or alkaline phosphatase up to> 20x ULN) or bili-
rubin (up to> 5x ULN) that trend downward to grade 2 or better by day 21 were prospectively
defined in the study protocol as expected and non-dose limiting.
Dose-limiting adverse events guided the rapid dose-escalation study plans. Grade 2 toxicity
in 1/1 dog triggered enrollment of an additional two dogs at that prescribed dose. DLT toxicity
in 1/3 dogs in a cohort necessitated cohort expansion (up to six dogs) to ensure tolerability.
The maximum tolerated dose was defined as one dose level below the maximum achieved in
the dose-escalation phase. Any and all adverse events were collected within the electronic data-
base reporting system (C3D) following strict one-week reporting timelines.
Biological collections
Whole blood, PBMCs, and serum were collected for all dogs. Pre- and post-treatment PBMCs
were collected for T-cell subset analysis on days 1, 2, 3, and 8. An eight-point pharmacokinetic
analysis of serum NHS-IL12, IFN-γ, and cytokine levels was performed pre-treatment (0 min-
utes), and at 1 hour, 2 hours, 4 hours, 8 hours, 24 hours, 32 hours, and 48 hours (prior to hospi-
tal discharge on day 3) after drug administration. Subsequent serum collections were made on
days 8, 15, 22, and 29. PBMCs were shipped the day of collection, while serum samples were
frozen and stored at -80°C until shipping. Samples collected up to and including day 8 were
mailed at the end of a dog’s first week on the study and all other samples were shipped at the
end of the study period.
Tumor biopsies
Dogs underwent a biopsy prior to receiving NHS-IL12 to establish a baseline for future evalua-
tions. Pre-treatment biopsies were incisional in nature and guided by the location of the tumor.
Keyes 6 mm punch biopsy instruments, 14g Tru-cut needle, and open biopsy techniques were
acceptable. Two pre-treatment samples were obtained at differing planes/angles within the
tumor. Each sample was sectioned, placed in formalin, RNAlater, and flash frozen. Similarly,
two post-treatment samples were obtained at differing planes/angles within the tumor on both
days 8 and 29 and processed as described above. Histopathologic analysis of tumor samples is
described below. Samples were stored at room temperature or -80°C respectively and shipped
at patient study completion for analysis.
Lymph-node fine-needle aspirates
Aspirates of regional lymph nodes draining the primary target lesion were performed when
applicable. Aspirates were collected on day 1 (pre-treatment), and on days 8 and 29 for flow
cytometry analysis to define subset populations of immune cells. Lymphoid populations were
characterized using dendritic and T- and B-cell markers: CD3, CD4, CD8, CD21, MHCII,
CD32, CD86, Treg/FoxP3, CD11c, CD40, and CD1a as described below.
Response assessment
Dogs that completed the 29-day study were evaluable for response. Clinical response at day 29
was based on RECIST criteria [22,23]. Dogs with PD or SD at day 29 were deemed off-study.
Dogs with resectable tumors at day 29 could undergo definitive resection, although this would
render them off-study. In the case of a measured response (PR or CR), dogs were evaluated
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monthly until PD was documented or other treatment was administered. Dogs were eligible to
continue receiving NHS-IL12 beyond day 29 (dogs with a PR or CR only) on an individual
patient basis. If PD was documented at any point during the study, even if prior to day 29, the
dog was removed from the study and permitted to receive other treatment according to the rec-
ommendations of their COTC site principal investigator.
NHS-IL12 structure and formulation
EMD-Serono generated a fusion protein (i.e. NHS-IL12), by transfection of Ab-p35 subunit
fusion constructs at the C-terminus into an NS/0 LD cell line already engineered to express
high levels of the p40 subunit of human IL-12 [33]. During the course of this study, 3 lots of
NHS-IL12 were administered to dogs (Non-GMP Lots # T07-009-12 and T09-001-3; GMP
engineering lot 1510A01). Lot number and date of use was recorded for all dogs.
NHS-IL12 subcutaneous administration
NHS-IL12 was administered subcutaneously on day 1. Dogs were eligible for retreatment every
28 days if they achieved an objective response by RECIST criteria. The dose was determined by
the NCI-COP based on an individual dog’s weight (converted into body surface area [m2]) and
study cohort where applicable (0.4 mg/m2; 0.8 mg/m²; 1.6 mg/m²; 2.4 mg/m²). The total pre-
scribed volume (1 ml) was delivered subcutaneously within the dorsal skin fold for all dogs.
Volume was standardized for all dogs and diluent added to each dosage as needed. A 22-gauge
needle was used for drug administration and the entire contents were dispelled prior to remov-
ing the needle from the subcutaneous space.
ELISA detection of serum NHS-IL12 levels for pharmacokinetics
analysis
For the detection of NHS-IL12 in serum samples, a commercially available human IL-12
ELISA kit (R&D Systems/Bio-Techne, Minneapolis, Minnesota) was used and further adapted
(calibration range: 31.3 to 2,000 pg/ml on plate; lower limit of quantitation in samples: 0.62
ng/ml). The kit includes microplates pre-coated with an anti-human IL-12 antibody. Serial
dilutions of NHS-IL12 protein were used as a calibration standard. Serum samples (run in
duplicate) were incubated in the assay plate for 2 hours before being washed and incubated
with a horseradish peroxidase-conjugated anti-IL-12 detection antibody. After another wash,
tetramethylbenzadine (TMB) chromogenic substrate was added. The reaction was stopped by
addition of an acid solution, and the optical density of each sample in the assay plate was deter-
mined using a microplate reader set at 450 nm. The concentration of NHS-IL12 in each serum
sample was calculated from a standard curve generated from a 4-parameter logistic curve-fit.
The assay was not evaluated for cross-reactivity to canine IL-12.
Immunogenicity analysis
Label-free surface plasmon resonance technology (Biacore Lifesciences/GE Healthcare Bio-Sci-
ences, Pittsburgh, Pennsylvania) was used to measure auto-antibody production to NHS-IL12.
For this purpose, CM5 Series S chips were coupled with either NHS-IL12 or purified human
IgG (Jackson Immuno Research, West Grove, Pennsylvania) for the detection of anti
NHS-IL12 antibodies. For analysis of the samples taken at later stages of the study course
(patients 0101, 0301, 0102, 1001, 0104, 0302, 0103, 0303, 1902, 1004, 0502, 0201), CM5 chips
were additionally coated with the p40 subunit of human IL-12 and the p70 dimeric recombi-
nant IL-12 in order to assess the immunogenic potential of the cytokine subunits of NHS-IL12.
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To avoid non-specific serum protein interaction with the chip surface, each of the serum sam-
ples was diluted with running buffer containing 1 mg/ml carboxymethyl dextran before analy-
sis. All test samples were injected over the chip surface and by subtracting the surface signal
after the sample injection from the surface signal prior to the sample injection, a binding signal
for that sample was calculated. No calibration curve was generated. Instead, the pre-treatment
samples taken from each dog were used as control samples to demonstrate positive binding sig-
nals. Antibodies to cytokines are routinely detected in both human and dog studies [34]. These
antibodies are expected to be neutralizing after 30–45 days of exposure.
ELISA detection of serum IFN-γ levels
IFN-γ in serum samples was detected using a commercially available canine IFN-γ ELISA kit
used according to the manufacturer’s protocol (R&D Systems, Cat# CAIF00). The kit includes
microplates pre-coated with an antibody specific for canine IFN-γ. A standard curve was cre-
ated using a recombinant canine IFN-γ standard. Serum samples (run in triplicate), and a
canine IFN-γ positive control, were incubated in the assay plate for 2 hours before being
washed and incubated with a canine-specific anti-IFN-γ-biotin conjugate. Following another
wash, detection was made by addition of a streptavidin-horse radish peroxidase conjugate, and,
after a final wash, TMB chromogenic substrate was added. The reaction was stopped by addi-
tion of an acid solution, and the optical density of each sample in the assay plate was deter-
mined using a microplate reader set at 450 nm. The concentration of IFN-γ in each serum
sample was calculated from a standard curve generated from a 4-parameter logistic curve fit.
Serum cytokine profiling
Serum cytokine panels quantified levels of IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, IL-15, IL-18,
GM-CSF, IFN-γ, IP-10, KC, MCP-1, TNF-α using the CCYTOMAG-90K canine cytokine/che-
mokine kit fromMillipore (Billerica, Massachusetts). Samples were prepared according to the
manufacturer’s instructions, with the exception of the following modifications: a) the volume
of all reagents used was halved, while keeping the concentration standard after validating this
approach by comparison with the recommended volume; and b) the highest concentration of
the standard curve was eliminated after the first 4 samples, since no dog’s cytokine/chemokine
levels approached this highest value. All samples were analyzed using a Bio-Plex 200 multiplex
assay system (Bio-Rad, Hercules, California).
Flow cytometry of PMBCs and regional lymph node samples
Blood was received on ice in EDTA blood collection tubes and analyzed as soon as received.
Red blood cells were lysed using a high salt solution consisting of 0.0005% phenol red, 150 mM
ammonium chloride, 10 mM potassium bicarbonate, and 0.1 mM EDTA (reagents from
Sigma, St. Louis, Missouri). PBMC or lymphocytes were added at a concentration of 5 x 105 to
1 x 106 per well in 96-well round bottom plates. Lymph node aspirates were washed once in
FACS buffer (PBS with 2% fetal bovine serum and 0.1% sodium azide) before being transferred
to round bottom 96-well plates. The cells were then centrifuged and washed using FACS buffer,
and cell pellets were resuspended in 10μl/well of blocking agent (normal canine serum, 16 μl/
ml human IgG, mouse anti-FCR III, and 0.05% sodium azide (all from Jackson Immunore-
search). Antibody combinations for flow cytometric analysis of T cells, B cells, and dendritic
cells were added in a 40 μl total volume as described below.
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B-cell panel for lymph node aspirates and white blood cells collected
from blood
1:10 mouse anti-canine CD21-PE (clone CA2.1D6; AbDSerotec, Raleigh, North Carolina) and
1:10 rat anti-canine MHC class II-FITC (clone YKIX334.2; AbDSerotec).
Dendritic-cell panel for lymph-node aspirates
1:1 mouse anti-canine CD11c primary antibody (clone CA11.6A1; AbDSerotec), secondary
antibody 1:200 F(ab)2 fragment donkey anti-mouse IgG-PE (Jackson Immunoresearch), and
1:10 rat anti-canine MHC class II-FITC (clone YKIX334.2; AbDSerotec).
T-cell panel for lymph node aspirates and white blood cells collected
from blood
1:200 rat anti-canine CD8-Alexa 647 (clone YCATE55.9; AbDSerotec) and 1:200 rat anti-
canine CD4-FITC (clone YKIX302.9; AbDSerotec).
Primary stains were incubated at room temperature for 30 minutes before being washed
twice in FACS buffer. Secondary antibodies were also incubated for 30 minutes at room tem-
perature in the case of the dendritic cell panel. T-cell panels were fixed and permeabilized
overnight in fixation/permeabilization buffer (eBioscience, San Diego, California). The follow-
ing day, T-cell panels were washed twice with 1X permeabilization buffer (eBioscience) diluted
in distilled water before being stained with 1:200 anti-mouse/rat Foxp3-PE (clone FJK16a;
eBioscience) for 30 minutes. A directly conjugated rat IgG2A antibody was used as the isotype
control. B-cell and dendritic-cell panels were fixed using a 1% solution of paraformaldehyde
for 20 minutes. All cells were washed an additional two times before being resuspended in
FACS buffer in cluster tubes ready for analysis by flow cytometry. Flow cytometry was carried
out on a Cyan flow cytometer (DakoCytomation/Beckman Coulter, Fort Collins, Colorado)
and Summit software for data analysis (DakoCytomation). Approximately 100,000 events were
analyzed for each sample. Analysis gates were set on the live lymphocyte population based on
typical forward- and side-scatter characteristics. The percentage of Tregs was calculated by
determining the percentage of FoxP3+CD4+ cells within the CD4+ T-cell population. The per-
centages of B cells, CD4+ and CD8+ T cells, and dendritic cells were also determined.
Histopathology and immunohistochemistry methodology
Hematoxylin and eosin (H&E) histologic analysis plus semi-quantitative scoring of necrosis
and extent/character of inflammatory infiltrates were performed for all tumor samples (pre-
treatment, days 8 and 29, and every 28 days thereafter, if appropriate). Immunohistochemistry
including CD3, CD4, CD8a, CD79a, CD18, and IL-12 plus photo documentation and semi-
quantitative scoring across the same study samples was also performed. Antibodies used for
immunohistochemistry are described below.
B-cell immunohistochemistry
Mouse monoclonal anti-human CD79a (1:125 dilution; Clone HM57, Dako Inc., Carpinteria,
California).
T-cell immunohistochemistry
Rat monoclonal anti-canine CD3e (1:20 dilution; Clone CD3-12; P. Moore, UC Davis, Califor-
nia); mouse monoclonal anti-canine CD4 (1:10 dilution; Clone CA13.1E4; P. Moore, UC
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Davis, California); mouse monoclonal anti-canine CD8 (1:10 dilution; Clone CA9.JD3; P.
Moore, UC Davis, California).
Beta-integrin (monocyte) immunohistochemistry
Mouse monoclonal anti-canine CD18 (1:10 dilution; Clone CA16.3C10; P. Moore, UC Davis,
California).
Serial sections from paraffin tissue blocks from each of the submitted formalin-fixed sam-
ples were deparaffinized, and rehydrated for routine immunohistochemical labeling. Immuno-
histochemical labeling was used to detect expression of CD18, CD3e, CD79a, and IL12RB2.
Deparaffinization, immunohistochemical labeling, and counterstaining was performed on the
Bond maX Automated Staining System (Vision BioSystems, Leica, Bannockburn, Illinois)
using the Bond Polymer Detection System (Vision BioSystems, Leica, Bannockburn, Illinois).
Antigen retrieval for CD3e and CD79a was done on the Bond maX Automated Staining System
by incubating slides with retrieval solution ER1 (Vision BioSystems, Leica, Bannockburn, Illi-
nois) for 20 minutes. Antigen retrieval for CD18 and IL12RB2 was achieved by incubation of
slides in antigen retrieval solution (Dako Inc, Carpinteria, California) in a steamer (Black &
Decker, New Britain, Connecticut) for 20 minutes. Primary antibodies and their dilutions,
source, and host are listed above. The immunoreaction was visualized with 3,3-diaminobenzi-
dine substrate (Vision BioSystems, Leica, Bannockburn, Illinois) and sections were counter-
stained with hematoxylin. Positive immunohistochemical controls included a normal canine
lymph node to which the appropriate anti-sera were added. For negative controls, the primary
antibodies were replaced with homologous non-immune sera. Only cytoplasmic/membrane-
associated labeling within cells was evaluated as positive. Additional serial sections of each
sample were stained with H&E according to routine protocols.
Serial sections of frozen tissue were cut on a Vibratome cryostat. Following fixation in cold
acetone (-20°C) for 3 minutes, immunohistochemical labeling for CD4 and CD8 was per-
formed on the Bench Mark Automated Staining System (Ventana Medical Systems, Inc., Phoe-
nix, Arizona) using the Ultra V-Red Detection (Alkaline Phosphatase Red) System with a
universal protein blocker (Dako Inc., Carpinteria, California). Sections were counterstained
with hematoxylin. Positive immunohistochemical controls included a normal canine lymph
node to which the appropriate anti-sera were added. For negative controls, the primary anti-
bodies were replaced with homologous non-immune sera. Only cytoplasmic/membrane-asso-
ciated labeling within cells was evaluated as positive. Additional serial sections of each sample
were stained with H&E eosin according to routine protocols.
CD8 Grading Scale
0 = no CD8+ cells; 1 = less than 10% of inflammatory cells are CD8+; 2 = 10–50% of inflamma-
tory cells are CD8+; 3 = more than 50% of inflammatory cells are CD8+.
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